STOCK TITAN

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Immunic Inc (Nasdaq: IMUX) has announced its participation in several key conferences during November 2024. The company will attend BIO-Europe in Stockholm (Nov 4-6) for partnering activities. At the Immuno-Mediated Diseases of the GI Tract Symposium in Florence (Nov 8-9), Dr. Sara Elhag will present data from their phase 1b trial of IMU-856, targeting SIRT6 in celiac disease patients. The company will also participate in the Jefferies London Healthcare Conference (Nov 19-21) and the Virtual Investor Summit (Nov 21), where CEO Daniel Vitt will present a company overview and conduct one-on-one meetings.

Immunic Inc (Nasdaq: IMUX) ha annunciato la sua partecipazione a diverse conferenze chiave durante novembre 2024. L'azienda parteciperà a BIO-Europe a Stoccolma (4-6 novembre) per attività di partnering. Al Simposio sulle Malattie Immuno-Mediate del Tratto Gastrointestinale a Firenze (8-9 novembre), la Dott.ssa Sara Elhag presenterà dati del loro trial di fase 1b di IMU-856, mirato a SIRT6 nei pazienti con celiachia. L'azienda parteciperà anche alla Conferenza Sanitaria Jefferies di Londra (19-21 novembre) e al Virtual Investor Summit (21 novembre), dove il CEO Daniel Vitt presenterà una panoramica dell'azienda e condurrà incontri one-on-one.

Immunic Inc (Nasdaq: IMUX) ha anunciado su participación en varias conferencias clave durante noviembre de 2024. La compañía asistirá a BIO-Europe en Estocolmo (del 4 al 6 de noviembre) para actividades de asociacionismo. En el Síntesis sobre Enfermedades Inmunitarias del Tracto Gastrointestinal en Florencia (del 8 al 9 de noviembre), la Dra. Sara Elhag presentará datos de su ensayo de fase 1b de IMU-856, dirigido a SIRT6 en pacientes con enfermedad celíaca. La empresa también participará en la Conferencia de Salud Jefferies en Londres (del 19 al 21 de noviembre) y en el Virtual Investor Summit (21 de noviembre), donde el CEO Daniel Vitt presentará una visión general de la compañía y llevará a cabo reuniones individuales.

Immunic Inc (Nasdaq: IMUX)는 2024년 11월에 여러 주요 회의에 참여할 예정이라고 발표했습니다. 이 회사는 BIO-Europe에 참석할 예정이며, 이는 스톡홀름에서(11월 4-6일) 파트너십 활동을 위한 것입니다. 소화관의 면역매개 질병 심포지엄이 피렌체에서(11월 8-9일) 열리며, 사라 엘하그 박사가 셀리악병 환자에서 SIRT6를 표적으로 하는 IMU-856의 1상 시험 데이터 발표를 할 것입니다. 또한 이 회사는 제퍼리스 런던 헬스케어 컨퍼런스 (11월 19-21일)와 버추얼 투자자 서밋 (11월 21일)에도 참여할 예정이며, CEO 다니엘 비트가 회사 개요를 발표하고 일대일 미팅을 진행할 것입니다.

Immunic Inc (Nasdaq: IMUX) a annoncé sa participation à plusieurs conférences clés en novembre 2024. La société assistera à BIO-Europe à Stockholm (du 4 au 6 novembre) pour des activités de partenariat. Au Symposium sur les maladies immunitaires du tractus gastro-intestinal à Florence (du 8 au 9 novembre), Dr Sara Elhag présentera des données de leur essai de phase 1b sur l’IMU-856, ciblant SIRT6 chez les patients atteints de la maladie cœliaque. La société participera également à la Conférence de santé Jefferies à Londres (du 19 au 21 novembre) et au Sommet virtuel des investisseurs (21 novembre), où le PDG Daniel Vitt présentera un aperçu de l’entreprise et effectuera des réunions individuelles.

Immunic Inc (Nasdaq: IMUX) hat seine Teilnahme an mehreren wichtigen Konferenzen im November 2024 angekündigt. Das Unternehmen wird an BIO-Europe in Stockholm (4.-6. November) teilnehmen, um Partnerschaften zu fördern. Auf dem Symposium über immunvermittelte Erkrankungen des Magen-Darm-Trakts in Florenz (8.-9. November) wird Dr. Sara Elhag Daten aus ihrer Phase-1b-Studie zu IMU-856 präsentieren, die SIRT6 bei Zöliakiepatienten angreift. Außerdem wird das Unternehmen an der Jefferies London Healthcare Conference (19.-21. November) und dem Virtual Investor Summit (21. November) teilnehmen, wo CEO Daniel Vitt einen Überblick über das Unternehmen geben und Einzelgespräche führen wird.

Positive
  • None.
Negative
  • None.

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November:

  • November 4-6: BIO-Europe. Members of Immunic's management, business development and investor relations teams will participate in partnering activities at this conference in Stockholm, Sweden. To schedule a meeting, please use the BIO-Europe partneringONE portal.

  • November 8-9: Symposium 238: Immuno-Mediated Diseases of the GI Tract: Where Do We Stand? Sara Elhag, Ph.D., Associate Manager Translational Pharmacology at Immunic, will present data from the company's phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a poster presentation at this symposium in Florence, Italy. The poster will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.

  • November 19-21: Immunic's management, business development and investor relations teams will be hosting one-on-one meetings in London in connection with the Jefferies London Healthcare Conference 2024. To schedule a meeting, please contact Jessica Breu, Vice President Investor Relations and Communications, at: jessica.breu@imux.com.

  • November 21: Virtual Investor Summit. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present a company overview on Thursday, November 21, 2024 and participate in one-on-one investor meetings at this conference. To listen to the company presentation, register for the conference using this link. The presentation and presentation time will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations, once they are available.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in industry, scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the UkraineRussia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information 

Immunic, Inc. 
Jessica Breu 
Vice President Investor Relations and Communications
+49 89 2080 477 09 
jessica.breu@imux.com 

US IR Contact 
Rx Communications Group 
Paula Schwartz 
+1 917 633 7790 
immunic@rxir.com 

US Media Contact 
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-industry-scientific-and-investor-conferences-in-november-302287361.html

SOURCE Immunic, Inc.

FAQ

What conferences will Immunic (IMUX) attend in November 2024?

Immunic will attend BIO-Europe (Nov 4-6), Immuno-Mediated Diseases Symposium (Nov 8-9), Jefferies London Healthcare Conference (Nov 19-21), and Virtual Investor Summit (Nov 21).

What will be presented at the GI Tract Symposium regarding IMU-856?

Dr. Sara Elhag will present data from Immunic's phase 1b clinical trial of IMU-856, a SIRT6 modulator, in celiac disease patients.

When is Immunic's CEO presenting at the Virtual Investor Summit?

CEO Daniel Vitt will present a company overview at the Virtual Investor Summit on November 21, 2024.

Where can investors access Immunic's (IMUX) presentation materials?

Presentation materials will be available on Immunic's website under the 'Events and Presentations' section at ir.imux.com/events-and-presentations.

Immunic, Inc.

NASDAQ:IMUX

IMUX Rankings

IMUX Latest News

IMUX Stock Data

97.29M
86.98M
3.44%
64.98%
4.99%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK